PortfoliosLab logoPortfoliosLab logo
ACRV vs. VTGN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACRV vs. VTGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Acrivon Therapeutics Inc. Common Stock (ACRV) and VistaGen Therapeutics, Inc. (VTGN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ACRV achieves a -32.37% return, which is significantly lower than VTGN's -4.47% return.


ACRV

1D
3.16%
1M
-6.86%
YTD
-32.37%
6M
-29.74%
1Y
38.14%
3Y*
-50.76%
5Y*
10Y*

VTGN

1D
-1.19%
1M
-2.27%
YTD
-4.47%
6M
-11.33%
1Y
-67.74%
3Y*
-28.22%
5Y*
-61.91%
10Y*
-40.14%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ACRV vs. VTGN - Yearly Performance Comparison


2026 (YTD)2025202420232022
ACRV
Acrivon Therapeutics Inc. Common Stock
-32.37%-59.97%22.36%-57.29%-13.71%
VTGN
VistaGen Therapeutics, Inc.
-4.47%-77.56%-42.61%66.34%-32.68%

Correlation

The correlation between ACRV and VTGN is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.30

Correlation (3Y)
Calculated over the trailing 3-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Nov 15, 2022

0.25

Fundamentals

Market Cap

ACRV:

$63.12M

VTGN:

$24.07M

EPS

ACRV:

-$2.00

VTGN:

-$1.88

PB Ratio

ACRV:

0.66

VTGN:

0.68

Total Revenue (TTM)

ACRV:

$0.00

VTGN:

$1.27M

Gross Profit (TTM)

ACRV:

$311.00K

VTGN:

$522.00K

EBITDA (TTM)

ACRV:

-$84.65M

VTGN:

-$68.97M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


VistaGen Therapeutics, Inc.

Often compared with ACRV:
ACRV vs. BVSACRV vs. HURAACRV vs. SSO
Often compared with VTGN:
VTGN vs. VT

Return for Risk

ACRV vs. VTGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACRV
ACRV Risk / Return Rank: 5959
Overall Rank
ACRV Sharpe Ratio Rank: 5757
Sharpe Ratio Rank
ACRV Sortino Ratio Rank: 6262
Sortino Ratio Rank
ACRV Omega Ratio Rank: 6262
Omega Ratio Rank
ACRV Calmar Ratio Rank: 5858
Calmar Ratio Rank
ACRV Martin Ratio Rank: 5656
Martin Ratio Rank

VTGN
VTGN Risk / Return Rank: 2222
Overall Rank
VTGN Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
VTGN Sortino Ratio Rank: 3131
Sortino Ratio Rank
VTGN Omega Ratio Rank: 3131
Omega Ratio Rank
VTGN Calmar Ratio Rank: 1414
Calmar Ratio Rank
VTGN Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACRV vs. VTGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Acrivon Therapeutics Inc. Common Stock (ACRV) and VistaGen Therapeutics, Inc. (VTGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ACRVVTGNDifference
Sharpe ratioReturn per unit of total volatility

+1.02

Sortino ratioReturn per unit of downside risk

+1.28

Omega ratioGain probability vs. loss probability

1.17

1.00

+0.17

Calmar ratioReturn relative to maximum drawdown

0.67

-0.76

+1.43

Martin ratioReturn relative to average drawdown

1.26

-1.08

+2.34

ACRV vs. VTGN - Sharpe Ratio Comparison

The current ACRV Sharpe Ratio is 0.42, which is higher than the VTGN Sharpe Ratio of -0.60. The chart below compares the historical Sharpe Ratios of ACRV and VTGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ACRV vs. VTGN - Drawdown Comparison

The maximum ACRV drawdown since its inception was -95.47%, roughly equal to the maximum VTGN drawdown of -99.76%. Use the drawdown chart below to compare losses from any high point for ACRV and VTGN.


Loading charts...

Drawdown Indicators


ACRVVTGNDifference

Max Drawdown

Largest peak-to-trough decline

-95.47%

-99.76%

+4.29%

Max Drawdown (1Y)

Largest decline over 1 year

-57.14%

-89.69%

+32.55%

Max Drawdown (3Y)

Largest decline over 3 years

-92.31%

-96.13%

+3.82%

Max Drawdown (5Y)

Largest decline over 5 years

-99.51%

Max Drawdown (10Y)

Largest decline over 10 years

-99.62%

Current Drawdown

Current decline from peak

-92.97%

-99.70%

+6.73%

Average Drawdown

Average peak-to-trough decline

-70.67%

-84.48%

+13.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.37%

62.61%

-32.24%

Volatility

ACRV vs. VTGN - Volatility Comparison

The current volatility for Acrivon Therapeutics Inc. Common Stock (ACRV) is 14.33%, while VistaGen Therapeutics, Inc. (VTGN) has a volatility of 25.47%. This indicates that ACRV experiences smaller price fluctuations and is considered to be less risky than VTGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ACRVVTGNDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.33%

25.47%

-11.14%

Volatility (6M)

Calculated over the trailing 6-month period

72.91%

50.23%

+22.68%

Volatility (1Y)

Calculated over the trailing 1-year period

92.04%

112.86%

-20.82%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

104.09%

320.41%

-216.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

104.09%

240.09%

-136.00%

Dividends

ACRV vs. VTGN - Dividend Comparison

Neither ACRV nor VTGN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ACRV vs. VTGN - Financials Comparison

This section allows you to compare key financial metrics between Acrivon Therapeutics Inc. Common Stock and VistaGen Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-800.00K-600.00K-400.00K-200.00K0.00200.00K400.00KJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
464.00K
(ACRV) Total Revenue
(VTGN) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ACRV and VTGN have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

VTGN has higher volatility (25.47%) compared to ACRV (14.33%). In terms of maximum drawdown, ACRV dropped -95.47% vs VTGN's -99.76%.

ACRV currently has the higher Sharpe Ratio (0.42 vs -0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ACRV and VTGN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer